Medifast (NYSE:MED) Downgraded to “Sell” Rating by Wall Street Zen

Medifast (NYSE:MED) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Other research analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (d)” rating on shares of Medifast in a research report on Thursday, January 22nd. Stephens reduced their price objective on shares of Medifast from $15.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Medifast presently has an average rating of “Reduce” and a consensus target price of $12.00.

Medifast Trading Up 0.1%

NYSE MED opened at $10.63 on Friday. Medifast has a 1-year low of $10.10 and a 1-year high of $15.48. The company has a 50 day moving average of $11.27 and a 200-day moving average of $12.27. The company has a market cap of $116.86 million, a price-to-earnings ratio of -6.22 and a beta of 0.53.

Medifast (NYSE:MED) last issued its quarterly earnings results on Tuesday, February 17th. The specialty retailer reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.21. Medifast had a negative return on equity of 4.27% and a negative net margin of 4.84%.The business had revenue of $75.10 million for the quarter, compared to the consensus estimate of $71.40 million. Medifast has set its FY 2026 guidance at -2.750–1.55 EPS and its Q1 2026 guidance at -0.700–0.15 EPS. On average, equities research analysts forecast that Medifast will post 0.51 earnings per share for the current year.

Institutional Trading of Medifast

Several large investors have recently bought and sold shares of MED. Amundi grew its position in Medifast by 43.5% in the first quarter. Amundi now owns 30,439 shares of the specialty retailer’s stock valued at $398,000 after acquiring an additional 9,224 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Medifast by 14.5% in the 1st quarter. AQR Capital Management LLC now owns 199,750 shares of the specialty retailer’s stock valued at $2,693,000 after purchasing an additional 25,366 shares in the last quarter. Strs Ohio bought a new stake in shares of Medifast during the 1st quarter valued at approximately $78,000. CWM LLC grew its holdings in shares of Medifast by 564.6% during the 2nd quarter. CWM LLC now owns 7,457 shares of the specialty retailer’s stock valued at $105,000 after purchasing an additional 6,335 shares during the last quarter. Finally, Allianz Asset Management GmbH acquired a new position in Medifast during the 2nd quarter worth approximately $307,000. 95.51% of the stock is owned by institutional investors and hedge funds.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.